|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, heterogeneous β-catenin activation drives HCC initiation and persists throughout hepatocarcinogenesis.
|
31575545 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The mutational status of the <i>CTNNB1</i> gene was determined in ß-catenin-activated HCA (b-HCA) and HCC with at least moderate nuclear CTNNB1 accumulation.
|
30901310 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
CircZFR promotes hepatocellular carcinoma progression through regulating miR-3619-5p/CTNNB1 axis and activating Wnt/β-catenin pathway.
|
30468709 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our results uncovered that Gankyrin functions as an essential regulator in glycolysis and glutaminolysis via activation of β-catenin/c-Myc to promotes tumorigenesis, metastasis and drug resistance in human HCC.
|
30503555 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
FAO induced by β-catenin oncogenic activation in the liver is the driving force of the β-catenin-induced HCC.
|
29650531 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Expression of a constitutively active β-catenin in Cav1 knockdown cells rescued FRMD5 expression and HCC tumorigenesis and metastasis.
|
30583072 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
It provides an improved understanding of molecular mechanisms underlying β-catenin activation and tumorigenesis in HCC.
|
31394122 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Furthermore, anabolic steroids are associated with hepatocellular carcinoma resulting from malignant transformation of β-catenin positive adenomas.
|
30955069 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In addition, whether lncRNA-DGCR5 can regulate Wnt/β-catenin pathway during HCC progression is unclear.
|
30230592 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
These data confirmed that the downregulation of MARCH1 could inhibit the progression of hepatocellular carcinoma and that the mechanism may be via PI3K/AKT/β-catenin inactivation as well as the downregulation of the antiapoptotic Mcl-1/Bcl-2.
|
30678274 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.
|
31142735 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Comprehensive molecular evaluation of HCC by multi-platform analysis defined three major subtypes: (1) mitogenic and stem cell-like tumors with chromosomal instability; (2) CTNNB1-mutated tumors displaying immune suppression; and (3) metabolic disease-associated tumors, which included an immunogenic subgroup characterized by macrophage infiltration and favorable prognosis.
|
30598371 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were not identified in any HCC-IS, while they were present in 24.1% of C-HCC (p = 0.016).
|
30930222 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Molecular changes in HCC collectively contribute to Wnt/β-catenin, as a tumor proliferative signaling pathway, toll-like receptors (TLRs), nuclear factor-kappa B (NF-κB), as well as the c-Jun NH2-terminal kinase (JNK), predominant signaling pathways linked to the release of tumor-promoting cytokines.
|
31827403 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
These findings unraveled a novel mechanism of c-Myc and Wnt/β-catenin interplay that dictates HCC pathogenesis, and have implications for the potential applicability of miRNA delivery in targeting the newly identified signaling axis and treating metastatic HCCs.
|
29653269 |
2018 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These results show that, although chronic CAR activation per se induces HCCs carrying β-catenin mutations, it concurrently down-regulates the Wnt/β-catenin pathway in nontumoral liver.
|
30201494 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
<b>Rationale:</b> Hepatocellular carcinoma (HCC) is an aggressive malignant solid tumor wherein CDK1/PDK1/β-Catenin is activated, suggesting that inhibition of this pathway may have therapeutic potential.
|
30083256 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of β-catenin and Yes-associated protein (YAP) signaling pathways has been associated with hepatocellular carcinoma (HCC) progression.
|
30041665 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis was used to measure the expression of hepatocyte growth factor receptor (c-Met), β-catenin and focal adhesion kinase (FAK) in patients with HCC. c-Met expression was identified to be high in patients with larger tumors, higher α-fetoprotein (AFP) levels, higher Edmondson grades, portal vein invasion and higher tumor-node-metastasis (TNM) stages.
|
29467897 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our study suggests plausible cell dedifferentiation mediated by β-catenin contributes to CSC-initiated HCC tumor growth in vivo.
|
30075764 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/β-catenin-induced FGF18 expression in hepatocellular carcinoma.
|
29242604 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
CDK7 activated beta-catenin/TCF signaling in hepatocellular carcinoma.
|
29981747 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
CCN1 is a target gene of β‑catenin in HCC and promotes the proliferation of HCC cells.
|
29286082 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Finally, we confirmed the correlation between M2 macrophage polarization and nuclear β-catenin accumulation in CD68<sup>+</sup> macrophages in human HCC biopsies.
|
30022048 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Further understanding the mechanisms involved in activating β-catenin/TCF signaling would benefit the treatment of HCC.
|
30319277 |
2018 |